Author: [email protected]

AstraZeneca’s $1.1B Investment in Next-Gen Vaccine Innovation via Icosavax

Posted on by [email protected]

Pharma giant AstraZeneca (AZN) announced Monday that it will purchase clinical-stage biotech Icosavax (ICVX) for up to $1.1 billion to augment its pipeline of vaccines targeting respiratory illnesses. Specifically, AstraZeneca aims to leverage Icosavax’s innovative virus-like particle (VLP) platform to develop a first-in-class combination vaccine against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

Icosavax’s novel VLP technology promises stronger efficacy, fewer side effects, and more durable protection than traditional vaccines – a potential game changer. And the biotech’s lead asset IVX-A12 delivered stellar phase 2 results earlier this year, prompting AstraZeneca to make this big bet on the future of infectious disease prevention.

Transformational Vaccine Approach

At the heart of this deal lies Icosavax’s VLP platform that engineers tiny proteins to mimic the structure of viruses and trigger a robust immune response. Think of VLPs as a sneaky way to train the body to fight off viruses without exposing it to any actual viral particles.

And the data so far indicates VLPs induce broader, more durable protection against infection than conventional vaccines. For example, the VLP approach is behind the extremely efficacious human papillomavirus and hepatitis B virus vaccines on the market today.

Icosavax builds on this proven concept with computationally designed VLPs targeting the unique antigens of RSV and hMPV. So AstraZeneca clearly coveted access to this next-generation technology that could change the way we immunize populations against common illness.

Expedited Path for Lead Asset

Central to the deal is Icosavax’s IVX-A12, a combo VLP vaccine to prevent RSV and hMPV, which both cause severe respiratory infection in the elderly and immunocompromised. IVX-A12 demonstrated outstanding immunogenicity – triggering enduring antibody responses – along with a clean safety profile in trials so far.

In fact, the vaccine’s phase 2 results were strong enough for the FDA to award IVX-A12 Fast Track designation. This promises an expedited path to approval given the high unmet need: there are no approved vaccines for older adults against these widespread, often dangerous pathogens.

So AstraZeneca leapfrogs development by 3-4 years via this acquisition rather than advancing an early-stage candidate itself. As part of a big pharma, IVX-A12 now has the resources for rapid phase 3 trials and submission for emergency use authorization potentially next year.

Aligns with Growth Strategy

Importantly, this deal fits squarely with AstraZeneca’s strategy of strengthening its portfolio in areas of high unmet need. As Executive VP Iskra Reic highlighted, adding IVX-A12 distinguishes AstraZeneca’s late-stage pipeline in preventative infectious disease treatments.

While the company already markets FluMist for influenza, a next-gen offering like IVX-A12 that could supplant outdated RSV vaccines or ineffective hMPV options would be a true differentiator. It also complements AstraZeneca’s leading COVID-19 antibody cocktail for immunocompromised patients unable to mount their own response.

Beyond the tech and pipeline boost, Icosavax also brings its experienced team and manufacturing capabilities to scale up production in anticipation of launch.

Investor Implications

Turning to the transaction itself, AstraZeneca’s upfront $15 per share offer in cash reflects a 43% premium to Icosavax’s December 9 close before rumors leaked. Including the $5 per share milestone payment, the total value exceeds $1 billion for a 91% premium.

Of course the back half requires IVX-A12 to gain approval and hit $750 million in sales, so some risk is baked in. But given peak revenue estimates exceeding $2 billion, this seems doable over 5-10 years post-launch.

Investors should watch for completion of the tender offer expected in Q1 2024. Passing majority shareholder approval should be straightforward with such a compelling premium. Then it becomes about execution – advancing IVX-A12 rapidly through late-stage trials.

Ultimately though, AstraZeneca makes a well-timed bet on revolutionary vaccine science that could elevate its infectious disease segment to new heights. And Icosavax investors get to participate in this next chapter via an up to 91% buyout windfall. Once again, merger mania in biopharma looks set to pay off handsomely.

Eagle Bulk Shipping to Merge with Rival to Create Dry Bulk Behemoth

Posted on by [email protected]

Dry bulk shipping company Eagle Bulk Shipping (EGLE) announced Sunday night that it has agreed to an all-stock merger with sector peer Star Bulk Carriers Corp. (SBLK). The deal will create one of the world’s premiere owners of dry bulk vessels with a combined fleet of 169 ships worth over $2 billion.

Under the terms of the agreement, Eagle shareholders will receive 2.6211 shares of Star Bulk for each Eagle share they currently hold. With Star Bulk shares closing at $19.95 on Monday, December 11, this values Eagle stock at $52.29 per share. Compared to Eagle’s actual close of $46.19 on Monday, this deal premium comes out to 13%.

Powerhouse in Making

The merger brings together two already sizable dry bulk fleets under one umbrella to better compete on costs and provide customers integrated solutions. For example, the combined entity can offer both Capesize vessels ideal for long haul bulk transport as well as Supramax ships designed for flexibility.

With over 150 million deadweight tonnage (DWT), the new entity will rank among the top five largest publicly-traded dry bulk owners globally. Management estimates at least $50 million per year in cost savings through operational synergies, consolidated corporate overhead, and improved purchasing leverage with suppliers.

And the company will maintain an industry-leading balance sheet with net debt of $1.4 billion equaling a reasonable 37% of its $2.1 billion capitalization. The merger therefore sets up the new Star Bulk as a dominant player in dry bulk shipping both in scale and efficiency. Noble Capital Markets Senior Research Analyst Michael Heim states in his latest research report that “the combined market capitalization of $2.1 billion and fleet of 159 ships makes it one of the largest in the world.”

Modern, Eco-Friendly Fleet

Critically, Star Bulk inherits an even more modern and environmentally-friendly fleet from Eagle. The average vessel age will drop to 11 years versus 14 years currently. Eagle’s ships were built at top-tier Asian shipyards known for quality and efficiency.

Just as important, Eagle has been an early and enthusiastic adopter of exhaust gas scrubbers which reduce harmful emissions. In fact, 97% of the combined fleet will now have these scrubbers installed well positioning the company for impending environmental regulations.

Maintaining a modern, eco-friendly fleet is increasingly important to winning business from customers like commodities giants Glencore and Trafigura who value corporate responsibility. So the transaction gives Star Bulk key competitive advantages on this front.

Market Perform on Limited Remaining Upside

With significant strategic rationale behind the merger, the analyst still downgraded Eagle stock to a Market Perform with limited additional upside. Specifically, they dropped their price target to $52 simply reflecting the implicit deal price.

So while the merger appears to make industrial sense and places fair long-term value on Eagle, investors shouldn’t expect much added price appreciation from current levels. Of course, there is a small chance the merger fails to close as anticipated allowing shares to diverge back downward.

But assuming smooth sailing through the expected close in 1H 2024, Eagle shareholders can take comfort in the 13% premium and exciting combined company outlook. This sets up Eagle owners to become owners in the industry’s next dry bulk titan.

Take a moment to take a look at more research on Eagle Bulk Shipping by Noble Capital Markets Analyst Michael Heim.

Endeavor Energy Partners Exploring Potential $30 Billion Sale

Posted on by [email protected]

Endeavor Energy Partners, the top privately-held oil and gas producer in the prolific Permian Basin of west Texas and New Mexico, is considering a sale that could value the company at an astonishing $25-30 billion, according to a recent Reuters exclusive.

The news comes fresh off the heels of some absolutely massive M&A action among public oil independents, with the $60 billion tie-up between ExxonMobil and Pioneer Natural Resources followed by Chevron announcing the $50+ billion purchase of Hess Corp. Now the private players are looking to capitalize on the consolidation wave by monetizing their substantial acreage as well.

Driving the potential multi-billion dollar valuation is Endeavor’s premier 350,000 net acre position in the coveted Midland sub-basin, the sweet spot of the larger Permian. With oil prices still hovering near $80 per barrel despite recession fears, there remain plenty of companies willing to pay up for high-quality acreage that can drive efficient growth for years to come. And Endeavor’s assets definitely check those boxes.

The Visionary Behind Endeavor’s Rise

Endeavor traces its roots back 45 years when Texas oilman Autry Stephens founded the small independent. The 85-year old Stephens grew the company through shrewd acreage acquisitions and by managing costs tightly with vertically integrated services businesses.

Now with retirement on the horizon, Stephens has apparently decided that the time is right to capitalize on the current market enthusiasm and secure his life’s work’s future by selling Endeavor to one of the large public independents like an Exxon or Chevron. Certainly Stephens’ estate and early investors would realize a tremendous windfall from such a deal.

While Endeavor has reportedly considered offers before, this time the process seems to be progressing firmly with investment bankers at JP Morgan already preparing marketing materials for potential buyers. So while there’s no guarantee that Endeavor finds a buyer or completes a sale, things have moved beyond the tire-kicking stage.

Ripe for the Picking by “Big oil”

As mentioned previously, Endeavor’s footprint in the core of the Permian Basin makes the company a logical target for any number of deep-pocketed suitors from major integrateds to large E&Ps looking to expand their presence.

And most of the likeliest buyers like Exxon, Chevron, and ConocoPhillips have all recently pulled off huge, multi-billion dollar deals to consolidate acreage while still leaving their balance sheets relatively unscathed. Using their equity and maintaining strong investment grade credit ratings remains paramount for the majors.

For example, Chevron structured its takeover of Hess Corp such that the $50 billion price tag amounted to less than half of its current cash position. So the company would have no issues stepping up to buy another large, complementary Permian pure-play.

Of course Exxon is in the same boat having expertly engineered the Pioneer acquisition to be immediately accretive to earnings and cash flow. So whileAbsorbing all of Endeavor’s 350k acres might be a bridge too far for XOM, the supermajor could easily swallow a chunk of the company or join a consortium.

Not to be outdone, ConocoPhillips recently closed its buyout of existing partner Lime Rock’s 50% stake in the Canadian Surmont oil sands project proving its appetite for sizable deals remains healthy. CEO Ryan Lance has also been vocal about wanting to bulk up the company’s Permianpresence over the long term giving it both the strategic rationale and financial means to pursue Endeavor.

Each of these independent E&Ps seem well suited to provide a soft landing for founder Autry Stephens’ life work. Endeavor has quietly built up a world class asset base that now looks poised to fetch an exceptional valuation and secure a new, well-heeled owner. So investors will be following the sales process closely as a potential deal would recalibrate the consolidation environment. Of course, we will have to wait and see what 2024 ultimately has in store for one of the Permian’s great growth stories.

Pushing the Frontiers: Innovation and Investment in Organ Transplantation

Posted on by [email protected]

The NobleCon19 panel discussion moderated by Nathan Cali, investment banker at Noble Capital Markets, on organ transplantation featured prominent figures in the field, including Dr. Karin Hehenberger, an organ transplant patient and founder of Lyfebulb, Dr. David Alexandre Gros, CEO of Eledon Pharmaceuticals, Dr. Muhammed Mohiuddin, director of the cardiac xenotransplantation program at the University of Maryland, and Dr. Pietr Witoski, surgery director of pancreatic and islet tranplant program at the University of Chicago. The discussion delved into their experiences, challenges in the organ transplant landscape, and revolutionary advancements, especially focusing on the concept of xenotransplantation.

Organ transplantation has come a remarkably long way since the first successful procedures in the 1950s and 60s. Yet there remain significant unmet needs and opportunities to further improve patient outcomes, quality of life, and access to these lifesaving procedures. At a presentation during NobleCon19, a panel of experts explored some of the latest breakthroughs and remaining challenges in areas ranging from immunosuppression to cross-species transplantation.

A Complex Treatment Paradigm

As patient-turned-advocate Dr. Karin Hehenberger related from personal experience, undergoing an organ transplant and living with a graft is filled with difficulties. The trauma of the surgery itself and needing immune-suppressing drugs just to avoid rejection deliver blows to physical health and mental wellbeing. This begins with a harrowing wait for a matching donor organ, continues through post-operative complications like infections, and extends for the rest of one’s life.

The panelists agreed the pressure on patients could be significantly reduced through innovation. More targeted immunosuppressants without harmful side effects would greatly improve quality of life after transplant surgery. Some emerging drug candidates like Eledon Pharmaceuticals Tegoprubart show early signs of progress on this front. There is also a global shortage of donor organs trailing far behind demand; new sources through xenotransplantation or regenerative medicine techniques could help resolve this shortage.

“We need a community where transplanted patients can come together, generate data, and advocate for change,” urged Dr. Hehenberger.

The valuable role of patient communities mirrors the interdisciplinary cooperation needed among the surgeons, specialists, social workers, and other caregivers that make organ transplantation successful. As Dr. Hehhenberger explained, the assessment process for transplant eligibility spans physical health, mental fitness, medication compliance, accessible transportation, and financial support. It is complex care with little margin for error.

An Evolving Market Landscape

Currently, the organ transplant market racks up over $5 billion in value each year and continues expanding at a steady pace. Much of this activity centers specifically around kidney transplants, where surgical innovations and public policy initiatives keep pushing the boundaries. As Dr. DA Gros noted, there are now a quarter million Americans living with a functioning kidney graft – proof of concept for an underappreciated treatment paradigm.

And yet, the surface has barely been scratched in terms of serving potential patients. Over half a million more remain tethered to dialysis as a stand-in for natural kidney function, with 125,000 added to this group annually in the U.S. alone. Dialysis generates its own burdens: decreased workplace productivity, infection risks, lower quality of life. From both humanitarian and financial viewpoints, empowering wider transition from dialysis to transplantation promises tremendous upside.

Experts on the panel targeted improved education around organ transplant options as a key opportunity. Many patients lack full information about the benefits transplant procedures can offer, or they confront social stigmas against this route. Policy revisions to widen access and increase support for lower-income patient communities could have an outsized impact as well.

Meanwhile, the business of organ transplantation continuously evolves. Major pharma companies like Bristol Meyers Squib remain heavily invested, yet a series of smaller players also drive momentum through novel immuno-therapy products. Audience members were encouraged to track firms like Aelix and Tacus for the next wave of clinical updates that will shape standard of care.

Pioneering the Future

Homing in on the future, speakers keyed in on barriers still to be conquered in transplantation medicine. While kidney procedures serve as a beachhead, there is a pressing need to expand reliable methods across more organ types while lengthening graft duration at the same time. This is no small task.

It will require rethinking conventional assumptions for a field that has relied predominantly on broad immune suppression since its inception. Some emerging biotech pipelines target specific T and B cell pathways implicated in chronic organ rejection, attempting to avoid toxicity associated with generalized immunosuppression. Early data hints at improved longevity for liver and heart grafts, but longer studies are still needed.

An even more radical solution highlighted by multiple panelists is the concept of xenotransplantation: introducing organs from other species like pigs into human patients. Recent demonstrations of human-pig heart and skin grafts saw patients survive months post-procedure compared to an anticipated span of days or weeks. The results electrified the transplant community given implications for essentially eliminating organ supply constraints.

That said, experts admit there are hurdles left to address before clinical adoption. Ethical quandaries exist around genetically modifying donor animals and infectious disease transmission risks from one species to another. Questions also persist about which immune pathways necessitate targeting for prolonged graft survival and how to refine the anti-rejection pharmaceutical regimens employed.

Signs point to countries with more flexible regulatory regimes as the likely springboards for refining xenotransplant methods and technology in the shorter-term. Yet the longer-term promise seems resoundingly clear. “If allowed, we will solve the organ shortage problem,” declared surgeon Dr. Peter Witoski when asked about outlook for the field.

A Call to Action

In closing the panel presentation, speakers underscored a sense of guarded optimism balanced with persistent unmet needs in transplantation medicine today. Limitations around donor organ supply and chronic graft failure continue exacting a real human toll, even if raw statistics showcase a steady rise in life-saving procedures overall.

It will take coordinated effort from policy makers, researchers, clinicians, investors and patient advocates to push new discoveries over the finish line – where they can impact the maximum number of lives. Key questions around optimal business models for novel therapeutics, data transparency, and equitable access are unlikely to solve themselves.

Yet the convergence of breakthrough technologies and innovative platforms for generating evidence, educating stakeholders and disseminating insights points toward a sea change for what the future may hold in this vital area of healthcare. The experts and audience members left the discussion around organ transplantation feeling energized to play their respective parts in driving that change.

Watch the webcast from The Organ Transplant presentation at NobleCon19 here

Saga Communications (SGA) – Compelling Total Return Potential

Posted on by [email protected]

Friday, December 08, 2023

Saga Communications, Inc. is a broadcast company whose business is primarily devoted to acquiring, developing and operating radio stations. Saga currently owns or operates broadcast properties in 27 markets, including 79 FM and 33 AM radio stations. Saga’s strategy is to operate top billing radio stations in mid sized markets, defined as markets ranked (by market revenues) from 20 to 200. Saga’s radio stations employ a myriad of programming formats, including Active Rock, Adult Album Alternative, Adult Contemporary, Country, Classic Country, Classic Hits, Classic Rock, Contemporary Hits Radio, News/Talk, Oldies and Urban Contemporary. In operating its stations, Saga concentrates on the development of strong decentralized local management, which is responsible for the day-to-day operations of the stations in their market area and is compensated based on their financial performance as well as other performance factors that are deemed to effect the long-term ability of the stations to achieve financial objectives. Saga began operations in 1986 and became a publicly traded company in December 1992. The stock trades on NASDAQ under the ticker symbol “SGA”.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Announces a hefty special dividend. The company announced that it declared a special cash dividend of $2.00 per share to be paid on January 12, 2024 to shareholders on record December 20, 2023. The aggregate amount of the special dividend of $12.5 million will be paid from its sizable cash position. We believe that the announcement reflects the company’s confidence in its favorable fundamental outlook and significantly strong financial position.

Strong balance sheet. As of Sept. 30, the company had $31.2 million in cash and no long term debt. As such, the company has a strong balance sheet that will be maintained following the special dividend payment. This recent dividend announcement follows its Board’s review of the appropriate level of cash to be maintained on its balance sheet, which will reduce cash and short term investments to roughly $25 million. 

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Xcel Brands (XELB) – Highlights From Noblecon19

Posted on by [email protected]

Friday, December 08, 2023

Xcel Brands, Inc. 1333 Broadway 10th Floor New York, NY 10018 United States https:/Sector(s): Consumer Cyclical Industry: Apparel Manufacturing Full Time Employees: 84 Key Executives Name Title Pay Exercised Year Born Mr. Robert W. D’Loren Chairman, Pres & CEO 1.27M N/A 1958 Mr. James F. Haran CFO, Principal Financial & Accou

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Noblecon19. On December 5th, management presented at Noblecon19 at Florida Atlantic University (FAU) in Boca Raton, Florida, to the investment community. The presentation conducted by Mr. Robert D’Loren highlighted the company’s transition to a high margin, licensing model, its recent announcement with super model Christy Brinkley, and the upcoming launch of its social commerce app. We believe that the company is well on its way for a transition toward revenue and cash flow growth. 

Strategic partnership. The company announced its newly formed joint venture with Christie Brinkley to develop TWRHLL, a lifestyle and apparel brand that will utilize retail and live streaming distribution channels. Christie Brinkley will serve as the face and voice of TWRHLL, which is expected to launch in the spring of 2024.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

AbbVie’s $8.7 Billion Acquisition of Cerevel Therapeutics: A Game-Changer for Neuroscience Innovations

Posted on by [email protected]

Pharmaceutical giant AbbVie made a huge splash in the neuroscience space this week with the announcement of its definitive agreement to acquire clinical-stage biotech Cerevel Therapeutics for $8.7 billion. This transforms AbbVie’s position in neuroscience and adds multiple late-stage assets to its pipeline that could drive significant growth over the next decade.

At $45 per share in cash, AbbVie is paying a hefty premium for Cerevel, reflecting its belief in the blockbuster potential of the company’s pipeline. Cerevel has built an impressive roster of new compounds for psychiatric and neurological conditions—areas where AbbVie already has an established presence with treatments for Parkinson’s disease and migraine but now gains even more scale.

The crown jewel of the deal is emraclidine, an investigational antipsychotic for schizophrenia and other psychiatric disorders that could set a new standard of care. Currently in late-stage development, emraclidine has shown early signs of superior efficacy and safety compared to existing schizophrenia meds. With schizophrenia impacting over 5 million people across developed markets, emraclidine represents a multibillion-dollar opportunity for AbbVie commercially.

Beyond emraclidine, Cerevel has a range of other clinical-stage neuro assets that strengthen and complement AbbVie’s pipeline. These include tavapadon for Parkinson’s, CVL-354 for depression, and darigabat for epilepsy—all of which have potential for best-in-class status in their respective categories.

Take a moment to take a look at Noble Capital Capital Market’s Senior Research Analyst Robert LeBoyer’s coverage universe.

According to AbbVie’s chairman and CEO Richard Gonzalez, “Our existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade.” He notes AbbVie’s global commercial infrastructure can help accelerate these drugs to market globally.

Gonzalez has orchestrated a highly successful strategy for AbbVie centered around building global therapeutic franchises in immunology, oncology, and aesthetics. Adding neuroscience as a fourth core franchise has been an ambition for awhile. Between Humira facing biosimilar competition and the need to fuel AbbVie’s next chapter of growth, this acquisition is a strategic step to position neuroscience as a more prominent piece of the puzzle.

For Cerevel, the buyout represents a major win and validation of the platform they have built. As CEO Dr. Ron Renaud comments, “Cerevel has always been committed to transforming what is possible in neuroscience…with AbbVie’s long-standing expertise in developing and commercializing medicines on a global scale, Cerevel’s novel therapies will be well positioned to reach more people.”

Wall Street is reacting positively to the deal announcement, with shares of both companies rising 3-4% the day it was announced. Investors recognize the growth implications and are cheering AbbVie’s move to recharge its pipeline.

While the deal is expected to close in 2024 pending approvals, it marks the continuation of a surge in biotech M&A driven by the appetite of large pharmas to augment their portfolios externally. With over 200 neuroscience programs in mid- to late-stage industrywide across CNS disorders, neurological treatments are having a moment right now. For AbbVie, the Cerevel transaction cements its intent to be at the forefront in capturing this opportunity.

Slowing Labor Market Still Relatively Strong Heading into 2024

Posted on by [email protected]

The latest US jobs data released this week points to a cooling labor market as the country heads into 2024, although conditions remain relatively strong compared to historical averages. The Labor Department reported there were 8.7 million job openings in October, down significantly from 9.4 million in September and the lowest level since March 2021.

While job growth is moderating, the labor market retains a level of resilience as employers appear reluctant to lay off workers en masse despite economic uncertainties. The quits rate held steady in October, indicating many Americans still feel secure enough in their job prospects to leave current positions for better opportunities.

However, the days of workers having their pick of jobs may be over, at least for now. Job openings have declined in most sectors, especially healthcare, finance, and hospitality – fields that had gone on major hiring sprees during the pandemic recovery. This reversal follows a series of steep Fed interest rate hikes aimed at cooling runaway inflation by dampening demand across the economy.

So far the Fed seems to have achieved a soft landing for the job market. Employers added a steady 150,000 jobs in October and unemployment remains low at 3.7%. The most recent data is welcome news for the Fed as it tries to bring down consumer prices without triggering a recession and massive job losses.

Heading into 2024, economists expect monthly job gains will average around 170,000 – still solid but below 2023’s pace when the economy added over 400,000 jobs a month. Wage growth is anticipated to continue easing as well.

While layoffs remain limited for now, companies are taking a more cautious stance on hiring, noted Nela Richardson, chief economist at ADP. “Business leaders are prepared for an economic downturn, but they are not foreseeing the kind of massive job cuts that happened in past downturns,” she said.

Some sectors still hungry for workers

Certain sectors continue urgently hiring even as the broader labor market slows. Industries like healthcare and technology still report hundreds of thousands of open jobs. Despite downsizing at high-profile firms like Amazon, the tech sector remains starved for engineers, developers and AI talent.

Demand still outweighs supply for many skilled roles. “We have around 300,000 open computing jobs today versus an average of 60,000 open computing jobs before the pandemic,” said Allison Scott, Chief Research Officer at KLA.

Restaurants and the wider hospitality industry also plan to bulk up staffing after cutting back earlier this year. American Hotel & Lodging Association CEO Katherine Lugar expects hotels to hire over 700,000 workers in 2024.

Traffic, bookings and travel spending are rebounding. “As we continue working our way back, hiring has picked up,” Lugar noted.

Uncertainties Cloud 2024 Outlook

Economists warn many uncertainties persist around inflation, consumer spending and business sentiment heading into 2024. “The outlook for next year is tough to forecast,” said Oren Klachkin of Oxford Economics. “A lot hinges on whether the Fed can tame inflation without severely harming employment.”

While the Fed intends to keep rates elevated for some time, markets increasingly expect a rate cut in 2024 if inflation continues cooling and economic growth stalls.

For jobseekers and workers, 2024 promises slower but steadier hiring without the wage bidding wars and unprecedented quitting rates seen last year. However, landing a new job may require more effort amid mounting competition.

The days of an ultra-tight labor market may have passed, but for now at least, most employers still remain eager to retain and recruit staff despite the slowing economy. The soft landing continues, but turbulence could still be ahead.

NobleCon19 Economic Perspectives – 2024: Boom or Bust?

Posted on by [email protected]


The Economic Perspectives Panel’s discussions at the recent NobleCon19 emerging growth conference not only provided valuable insights into various sectors and the broader economic landscape but also served as a comprehensive analysis that captivated the audience’s attention. The panel, featuring a diverse range of experts from industry leaders to economists, offered nuanced perspectives on the challenges that have characterized markets since 2021 and identified potential opportunities, notably emphasizing the potential for undervalued small-cap investments.

The conference kicked off with an Economic Outlook Panel, expertly moderated by Michael Williams, a seasoned News Anchor at WPTV/NBC in West Palm Beach. Williams adeptly steered the discussions through key topics, leveraging the wealth of knowledge from panelists such as Lisa Knutson, COO of E.W. Scripps; Cary Marshall, CFO of Alliance Resource Partners; Jose Torres, Senior Economist at Interactive Brokers; Shanoop Kothari, Co-CEO of LuxUrban Hotels; and Dan Thelen, Managing Director of Small/Mid Caps at Ancora.

A prevailing sentiment among the panelists was the intriguing possibility of 2024 mirroring the economic resurgence experienced in 1990, a year that followed a challenging period. Notably, the consensus was that small-cap investments tend to outperform larger companies during economic recoveries due to their inherent agility and greater potential for growth. The panel expressed cautious optimism, suggesting that the Russell 2000 index might pleasantly surprise investors in the upcoming year.

The discussion also spotlighted sectors of particular interest, with media and advertising taking center stage. The anticipation of heavy political ad spending, estimated at an impressive $10-12 billion leading up to the 2024 election, captured the attention of the panel. Additionally, the oil and gas markets were under scrutiny, with a notable supply response identified as a contributing factor in curbing recent inflation concerns. Projections indicated a forecasted addition of 2.2 million extra barrels per day in the US in 2023, with prices already having experienced a 17% drop from their earlier peak in the year.

Delving into broader economic discussions, the panel highlighted the resilience observed in 2023 to date, supported by a robust labor market and excess pandemic savings fueling consumption. However, the panel cautioned against undue optimism, pointing to expectations of a potential slowdown in 2024, particularly as the Federal Reserve eases interest rates and government spending recedes. The acceptance of a 3-3.5% baseline inflation in the long term was posited as a necessary acknowledgment, notwithstanding the official 2% target.

While acknowledging potential risks in the commercial real estate sector, the panel expressed confidence that forward-thinking companies were actively engaged in cost-cutting measures and prudent inventory management. The overarching expectation was that stock returns would follow a trajectory reminiscent of the positive trends witnessed in 1990, thereby making small-cap investments an attractive prospect for investors keen on capitalizing on emerging opportunities.

Addressing the transformative impact of artificial intelligence (AI) on various facets of business and society, the panel collectively agreed that AI is not just a passing trend but a transformative force that is here to stay. Cary Marshall went as far as declaring, “AI is the electrification of this country.” While recognizing the potential for AI to reduce labor costs, the panelists cautioned that widespread adoption might take longer than initially anticipated. Jose Torres added a nuanced perspective, suggesting that AI could lead to shorter workdays but expressed concerns about the potential erosion of interpersonal skills critical for persuasion and influence.

In conclusion, the panel emphasized the indispensable need for mental toughness, emotion management, and discipline in navigating the inevitable cycles of the markets. Despite the multifaceted challenges, the prevailing sentiment was one of guarded optimism for the road ahead. As markets continue to evolve and present new dynamics, these key takeaways from the Economic Perspectives Panel offer invaluable insights for investors seeking to navigate the intricate landscape of emerging growth and economic recovery, providing a robust foundation for strategic decision-making in the ever-changing financial environment.

Gold Glitters as Prices Continue Record-Breaking Surge

Posted on by [email protected]

Gold prices have been on a dazzling run in recent months, with the precious metal notching consecutive monthly gains to reach new all-time highs. On Monday, spot gold prices topped $2,100 an ounce for the first time ever, hitting $2,110 before pulling back slightly. This adds to the previous record set back on Friday when prices exceeded $2,075, blowing past 2020’s earlier high point.

Analysts say gold still has room to run in 2023 and 2024 as key conditions line up to support further upside for bullion. Low interest rates, a weakening US dollar, rising inflation concerns globally, and an array of simmering geopolitical conflicts should all conspire to keep safe haven demand elevated.

“There is simply less leverage this time around versus 2011 in gold,” said Nicky Shiels of MKS PAMP, noting that the current dynamics put $2,200/oz within reach. Other experts concur, with UOB strategist Heng Koon How targeting $2,200 gold by end-2024, and TD Securities anticipating average prices around $2,100 in Q2 2024.

Fueling this gold fever has been robust central bank buying, especially across emerging markets. Recent data shows 24% of central banks worldwide intend to pad their gold reserves over the next year as economic uncertainty persists. With these institutions showing waning faith in traditional reserve assets like the US dollar, their bullion accumulation provides a sturdy pillar of support.

Geopolitical Flare-Ups Stoke Safe Haven Appeal

Mounting geopolitical tensions represent another propellant behind gold’s rise. The bloody conflict between Israel and Palestine has recently stoked investor fears, driving many towards gold’s relative stability. Looking ahead, strategists believe various other hotspots could flare up and lift bullion demand more.

Besides the Middle East, worsening frictions between China and Taiwan or a resurgence of the crisis in Ukraine could shock markets. And if the US gets dragged into any new foreign entanglements, it may have to ramp up defense spending and borrowing, potentially weakening both growth and the dollar.

With so many risks swirling, portfolio managers and retail buyers appear increasingly eager to hedge with gold. Notably, demand has climbed even as gold prices touched multi-year highs. This underscores bullion’s unique status as a tried-and-true safe haven asset.

Fed Policy Outlook Could Offer Further Boost

Though gold has powered higher despite a spate of Fed rate hikes, any change in this tightening cycle would provide another major catalyst. After lifting interest rates rapidly from near-zero, policymakers must now decide whether to keep tightening or ease off the brakes.

Several officials, including Governor Christopher Waller, have hinted rates may not rise much further if inflation keeps slowing as expected. Markets thus see potential Fed rate cuts arriving sometime in 2024.

If implemented, this dovish shift would likely hamstring the dollar and bond yields, stirring more demand for non-interest-bearing gold. Hence analysts view Fed pivots as a probable linchpin that keeps prices locked above $2,000 over the next couple of years.

With stars aligned for gold both fundamentally and geopolitically, all the ingredients seem in place for its dazzling run to continue. That leaves bulls dreaming ever more ambitiously of how high prices could yet soar. However, given gold’s inherent volatility, traders should steel themselves for pullbacks as well while enjoying the ride upwards.

Powell Pumps the Brakes on Rate Cut Hopes

Posted on by [email protected]

Federal Reserve Chair Jerome Powell threw cold water on mounting speculation that the central bank is nearing the end of its tightening campaign and will soon reverse course to cutting interest rates.

In a speech at Spelman College on Friday, Powell asserted “it would be premature” for investors to conclude the Fed’s policy stance is restrictive enough given lingering inflation pressures. He stated plainly that more rate hikes could still be on the table if appropriate.

His sobering comments follow the latest inflation data showing core PCE, the Fed’s preferred gauge, ticked down slightly to 3.5% annually in October. Though marking a fourth consecutive month of slow improvement, Powell emphasized the number remains well above the Fed’s 2% target.

“While the lower inflation readings of the past few months are welcome, that progress must continue if we are to reach our 2% objective,” he said.

Nonetheless, overeager investors have jumped the gun on declaring victory over inflation and penciling in imminent rate cuts. Billionaire Bill Ackman predicted this week that cuts could come as soon as Q1 2024.

But Powell asserted the full impact of the Fed’s blistering pace of rate hikes this year has likely not yet transmitted through the economy. Plus, he noted core PCE has averaged 2.5% over the past six months – still too high for comfort.

Key Takeaways for Investors

The Fed chair’s remarks make clear that policymakers see their inflation-taming mission as incomplete despite markets cheering each new downward tick. Here are the big implications for investors:

  • Rate cuts are not coming anytime soon. The Fed wants concrete evidence that inflation is reverting steadily to its 2% goal before it contemplates easing policy. Powell admission that more hikes could happen dispels investor hopes for a swift policy pivot.
  • Stocks may face renewed volatility. Exuberant bets on imminent rate cuts provided major tailwinds for this year’s risk asset rebound. With the Fed dampening that narrative, investors may recalibrate positions. Powell cautioned about the unusual uncertainty still permeating the economic outlook.
  • Recession risks linger in 2024. The full brunt of the Fed’s Super-Size rate hikes has yet to impact the real economy. Powell made clear policy will stay restrictive for some time to have its intended effect of slowing demand and consumer spending. That keeps recession risks on the radar, especially in the back half of next year.

Navigating the Volatility Ahead

With the Fed determined to remain the grinch raining on investor enthusiasms around pivots, next year promises more turbulence for markets. Savvy investors should:

Trim exposure to interest-rate sensitive assets: Risks remain heavily skewed towards more volatility as the Fed asserts its hawkish credibility. ratchet down exposure to bonds, utilities, real estate and other rate-vulnerable sectors.

Emphasize inflation hedges: The Fed’s clear-eyed focus on returning inflation to 2% means investors should still prioritize inflation-fighting assets like commodities, TIPS, floating-rate bank loans, and short-duration bonds. These provide buffers against rising prices.

Stay nimble amid cross-currents: Between lingering inflation and slowing growth, crosswinds for investors abound. Being opportunistic yet disciplined will be critical, as risk appetites could sour quickly depending on upcoming data and guidance from the Fed. Maintaining flexibility and even selective hedges allows investors to adeptly navigate the turbulence ahead under Powell’s resolute hawkish watch.

Pfizer Weight Loss Pill Hits Snag in Mid-Stage Trial

Posted on by [email protected]

Pharmaceutical giant Pfizer suffered a setback this week in the high-stakes race to tap into the burgeoning multi-billion dollar weight loss drug market. The company announced it is halting development of the twice-daily formulation of its experimental obesity pill danuglipron after underwhelming mid-stage trial results.

While the drug induced significant weight loss in obese patients, it came at the cost of poor tolerability. Over half of participants dropped out of the phase 2 study due to adverse gastrointestinal side effects like nausea and diarrhea.

Nonetheless, Pfizer still intends to stay in the game with a once-daily version of danuglipron. The company aims to release fresh phase 2 data on the more competitive formulation in early 2024 before determining next steps.

For a drugmaker grappling with fading Covid-19 revenues, the news deals a tough blow to its strategy to offset declines through potential new blockbusters for obesity. Just last year, CEO Albert Bourla tagged the total addressable weight loss market at a whopping $90 billion.

But competition is cutthroat, with Novo Nordisk and Eli Lilly vying to convert millions from their injectable diabetes meds to an oral option. Their rival pills have already posted mid-teens percentage weight loss results that position them to potentially leapfrog Pfizer’s attempt.

Danuglipron Quick Facts

  • Twice-daily formulation now discontinued after 6.9% to 11.7% weight loss at 32 weeks
  • Well below 14-15% loss seen as competitive threshold
  • High rates of nausea, vomiting, diarrhea
  • Over 50% dropout rate

Key Takeaways for Investors
The disappointing data for danuglipron’s twice-daily pill underscores several investor concerns around Pfizer’s efforts to expand into weight loss medicines.

Uphill Battle Against Rivals
Novo Nordisk and Eli Lilly already dominate the obesity drug landscape with their injectable products Saxenda and Ozempic. Lilly’s oral candidate tirzepatide is showing roughly 15% weight loss over 72 weeks, clearing the competitive bar Pfizer failed to hit.

While the field is large enough for multiple winners, Pfizer faces substantial share challenges from these deeply entrenched rivals. Its best-case outcome may be carving off a small slice rather than market leadership.

Tolerability Issues Limiting
Danuglipron has now faltered twice in mid-stage studies due to side effects leading over half of volunteers to quit treatment. The once-daily route shows some promise, but gastrointestinal problems may hamper uptake if they persist. By comparison, tirzepatide posted a 21% dropout rate.

Uncertainty Remains High
With phase 3 trials still a distant prospect, the program faces a long road ahead fraught with risk. While danuglipron evinced significant weight-loss efficacy, real-world commercial success depends greatly on improving its poor tolerability profile.

Until then, uncertainty around Pfizer’s weight loss aspirations stays high. Expect sales projections to remain muted absent positive late-stage outcomes down the line. But rivals like Lilly and Novo aren’t standing still either, making danuglipron’s path ahead even trickier.

Inflation Edges Higher in October but Shows Ongoing Signs of Cooling

Posted on by [email protected]

New government data released Thursday indicates that inflation ticked slightly higher in October but remained on a broader cooling trajectory as price pressures continue moderating from 40-year highs reached earlier this year. The report provides further evidence that the rapid pace of price increases may be starting to steadily decelerate, supporting the Federal Reserve’s recent inclination to halt its aggressive interest rate hike campaign.

The Fed’s preferred inflation gauge, the core personal consumption expenditures (PCE) price index, rose 0.2% last month and 3.5% over the past year. This matched consensus economist forecasts. The core PCE index strips out volatile food and energy costs to provide a clearer view underlying price trends.

While still well above the Fed’s 2% target, the annual increase was down from 5.3% in February. The incremental monthly gain showed prices climbing at a more restrained pace after an intense burst earlier this year.

“The Fed is on hold for now but their pivot to rate cuts is getting closer,” said Bill Adams, chief economist at Comerica Bank. “Inflation is clearly slowing.”

Markets are already betting policymakers won’t hike rates again this cycle, and may even start cutting in 2024 to bolster growth as price pressures continue easing. The latest data provides credibility to the idea that the Fed’s rapid rate hikes since March, which have raised its benchmark to a 15-year high, have begun achieving their intended effect of reining in demand and cooling the economy enough to tame inflation back toward manageable levels.

Still Cautious on Further Easing

However, Fed officials stressed that rates will still need to remain at restrictive levels for some time to ensure inflation continues descending toward the central bank’s 2% target.

New York Fed President John Williams said Thursday he expects inflation to keep drifting lower, finally hitting the Fed’s goal by 2025. But he emphasized rates will likely need to stay elevated until then to completely quell price pressures.

Other Fed policymakers also struck a cautious tone on prematurely ending rate hikes before inflation is convincingly on a path back towards the 2% goal. Many noted that while price increases may be peaking, inflation remains stubbornly high and consumer demand continues holding up more than feared despite rapid rate rises this year.

Moderating Labor Market Could Allow Rate Cuts

There were some early signs in Thursday’s data that the torrid job market may also finally be cooling slightly after persisting at unsustainable levels through much of the year.

The report showed continuing jobless claims climbed to 1.93 million in mid-November, their highest mark since November 2021. The number of Americans applying for ongoing unemployment benefits has risen by more than 80,000 since October.

While still historically low, the increase could provide Fed officials confidence that their rate hikes have begun not only slowing demand and price growth, but also easing excessively tight labor market conditions they have said contributed to rapid wage and inflation surges.

An easing job market that reduces wage pressures could give the Fed leeway next year to shift their priority toward sustaining growth and cut rates to spur a slowing economy, especially as other inflationary pressures subside.

Consumers Keeping Pace For Now

On the growth side, the report showed some signs of resilience among consumers even in the face of elevated inflation and rising borrowing costs.

Personal income and consumer spending both edged up 0.2% in October, indicating households are so far keeping pace with rising prices digging into their paychecks. Services like travel and healthcare saw particularly solid spending last month.

Surveys show consumers remain relatively upbeat thanks to still-ample savings and solid income growth. But many Fed officials have noted anecdotally that households appear to be pulling back spending more than aggregate data indicates so far. Any sharper-than-expected deceleration in consumer demand would give policymakers leeway to pivot toward supporting growth.

Eyes on Services Inflation

Some economists noted that while goods prices have cooled sharply from peaks last year amid improving supply issues, services costs remain stubbornly high for now as resilience in consumer demand combined with rising wage growth enables firms to pass higher labor expenses to customers.

“Inflation is moderating with goods prices leading the charge,” said economist Nancy Vanden Houten of Oxford Economics. But she said core services costs actually ticked up in October, bearing monitoring to ensure price stability as the economy shifts more toward services consumption over goods.

With strong income gains and accumulated savings still underpinning spending for now, officials emphasized rates may need to stay higher for longer to ensure the progress made on easing price pressures sticks.

“I expect it will be appropriate to maintain a restrictive stance for quite some me to fully restore balance and to bring inflation back to our 2 percent longer-run goal on a sustained basis,” said the New York Fed’s Williams on Thursday.